Tivicay (dolutegravir) – Generic Availability
| Region | Current Status | Expected Generic Availability |
|--------|----------------|------------------------------|
| United States | Tivicay is the brand‑name product sold by Gilead. The primary patents protecting the drug are set to expire in 2025 (the main “patent” that covers the drug’s formulation and use). | The first U.S. generic version is anticipated to be approved by the FDA in 2024 – one year before the patents fully expire – as a “patent‑challenging” generic. If the FDA does not approve a generic in 2024, it is likely to be available in 2025 or 2026, once the patents lapse. |
| Europe / UK | Gilead holds a similar patent portfolio, and the European Medicines Agency (EMA) has not yet approved a generic. | In many EU countries, the generic is expected to be available 2024–2025, depending on when the EMA grants approval. |
| Other Countries | Availability varies by country‑specific regulatory approvals and patent status. | Generic dolutegravir could enter the market as early as 2024 in jurisdictions with more aggressive patent‑challenging pathways, but each country’s drug‑approval authority must approve the product first. |
---
Why the 2024–2025 Window?
1. Patent Lifecycle
* The original U.S. patent that covers dolutegravir’s composition and use was filed in 2007 and is set to expire in 2025.
* Gilead has secondary patents (e.g., formulation, delivery method) that extend protection a bit longer, but the key “use” patent expires in 2025.
2. FDA’s Generic Pathway
* Generics can be approved before the final patent expires via a “patent‑challenging” route (Section 505(b)(2) of the FDCA).
* Several generic manufacturers have already filed applications, and the FDA has indicated that the first approval is expected in late 2024.
3. Market Dynamics
* Once the generic is approved, it usually takes a few months for it to become commercially available, so patients could expect to see the generic on pharmacy shelves in early 2025.
---
Practical Take‑aways for Patients
- If you’re on Tivicay in the U.S.: Talk to your prescriber or pharmacist about the possibility of a generic switch once it becomes available.
- If you’re traveling or living abroad: Check the local drug‑approval authority for the earliest generic approval date.
- Cost Impact: The generic is projected to be 30–50 % cheaper than the brand, which could improve affordability for many patients.
---
Bottom line: Expect the first U.S. generic version of Tivicay (dolutegravir) to be approved around late 2024, with the drug likely available to patients by early 2025. In the EU, the generic is expected around the same time, but the exact date depends on each country’s regulatory approval.